Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRTX NASDAQ:INCR NASDAQ:INZY NASDAQ:LFCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.32-28.3%$2.00$1.04▼$2.68$280.72M1.15938,249 shs14.95 million shsINCRInterCure$1.50+0.7%$1.51$1.17▼$2.30N/A1.1836,671 shs32,015 shsINZYInozyme Pharma$4.00$3.99$0.72▼$6.24$258.25M2.27960,267 shsN/ALFCRLifecore Biomedical$7.24-6.7%$7.46$3.68▼$8.85$287.32M0.65122,856 shs171,759 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics-28.26%-21.89%-40.81%-37.44%-34.00%INCRInterCure+1.01%+4.17%-5.66%-5.66%-26.11%INZYInozyme Pharma0.00%0.00%0.00%+244.83%-7.19%LFCRLifecore Biomedical-6.70%+3.58%-11.17%+3.87%+50.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHRTXHeron Therapeutics3.6845 of 5 stars3.51.00.04.21.71.70.6INCRInterCureN/AN/AN/AN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/AN/AN/AN/ALFCRLifecore Biomedical1.3377 of 5 stars2.30.00.00.01.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRTXHeron Therapeutics 3.00Buy$4.50240.91% UpsideINCRInterCure 0.00N/AN/AN/AINZYInozyme Pharma 2.44Hold$11.75193.75% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0010.50% UpsideCurrent Analyst Ratings BreakdownLatest INCR, LFCR, INZY, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.006/9/2025HRTXHeron TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold5/16/2025INZYInozyme PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.005/16/2025INZYInozyme PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$15.00 ➝ $4.005/14/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRTXHeron Therapeutics$144.29M1.40N/AN/A($0.22) per share-6.00INCRInterCure$64.55MN/AN/AN/A$2.36 per shareN/AINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ALFCRLifecore Biomedical$128.87M2.08N/AN/A$0.37 per share19.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRTXHeron Therapeutics-$13.58M-$0.06N/AN/AN/A-5.24%N/A-3.43%8/11/2025 (Estimated)INCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%N/ALFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-31.70%-696.62%-12.94%10/3/2025 (Estimated)Latest INCR, LFCR, INZY, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025Q4 2025LFCRLifecore Biomedical-$0.09N/AN/AN/A$35.36 millionN/A8/11/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 millionN/A5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRTXHeron TherapeuticsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRTXHeron TherapeuticsN/A2.401.76INCRInterCure0.341.731.18INZYInozyme Pharma0.652.192.19LFCRLifecore Biomedical66.362.711.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRTXHeron Therapeutics80.01%INCRInterCure8.34%INZYInozyme Pharma88.30%LFCRLifecore Biomedical83.36%Insider OwnershipCompanyInsider OwnershipHRTXHeron Therapeutics5.86%INCRInterCure0.24%INZYInozyme Pharma12.18%LFCRLifecore Biomedical32.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRTXHeron Therapeutics300152.56 million143.62 millionOptionableINCRInterCure350N/AN/AOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableLFCRLifecore Biomedical69037.03 million25.10 millionOptionableINCR, LFCR, INZY, and HRTX HeadlinesRecent News About These CompaniesLifecore Biomedical, Inc. (LFCR) Q4 2025 Earnings Call TranscriptAugust 8 at 10:06 AM | seekingalpha.comLifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate UpdateAugust 7 at 4:18 PM | globenewswire.comLifecore Biomedical (LFCR) to Release Quarterly Earnings on ThursdayAugust 5, 2025 | marketbeat.comDCF Advisers LLC Sells 56,989 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)August 4, 2025 | marketbeat.comLifecore Biomedical, Inc. to Report Q4 and Fiscal Year 2025 Financial Results on August 7, 2025July 31, 2025 | quiverquant.comQLifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025July 31, 2025 | globenewswire.comLaughing Water Capital’s View on Lifecore Biomedical (LFCR)July 24, 2025 | finance.yahoo.comLaughing Water Capital’s View on Lifecore Biomedical Inc. (LFCR)July 24, 2025 | insidermonkey.comLifecore Biomedical (NASDAQ:LFCR) Trading Down 2.5% - What's Next?July 19, 2025 | marketbeat.comLifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 17, 2025 | globenewswire.comLifecore Biomedical Insider Ups Holding During YearJuly 7, 2025 | finance.yahoo.comLifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic TherapyJune 18, 2025 | kalkinemedia.comKLifecore Biomedical: Inflecting Financials Over Next 3 YearsJune 18, 2025 | seekingalpha.comLifecore Biomedical signs new 10-year commercial manufacturing and supply agreementJune 17, 2025 | msn.comBronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to ConnectJune 17, 2025 | accessnewswire.comALifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing CustomerJune 17, 2025 | globenewswire.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationJune 15, 2025 | accessnewswire.comALifecore Receives Full Payment Early For $17 Mln Equipment SaleJune 14, 2025 | nasdaq.comLifecore Biomedical, Inc.: Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment SaleJune 12, 2025 | finanznachrichten.deBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the InvestigationJune 12, 2025 | accessnewswire.comALifecore Biomedical receives accelerated payment of remaining $10M in proceeds from equipment saleJune 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesThe 4 Dividend Stocks Smart Money Is Grabbing Right NowBy Thomas Hughes | July 24, 2025View The 4 Dividend Stocks Smart Money Is Grabbing Right Now4 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q24 Major Stocks Raise 2025 Guidance, Analyst Targets RiseBy Leo Miller | July 23, 2025View 4 Major Stocks Raise 2025 Guidance, Analyst Targets RiseKinder Morgan: At the Hotspot of the Natural Gas RevolutionBy Thomas Hughes | July 21, 2025View Kinder Morgan: At the Hotspot of the Natural Gas RevolutionGameStop: Clarity Brings Renewed Confusion for Meme StockBy Thomas Hughes | July 22, 2025View GameStop: Clarity Brings Renewed Confusion for Meme StockINCR, LFCR, INZY, and HRTX Company DescriptionsHeron Therapeutics NASDAQ:HRTX$1.32 -0.52 (-28.26%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.38 +0.06 (+4.55%) As of 08/8/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.InterCure NASDAQ:INCR$1.50 +0.01 (+0.67%) Closing price 08/8/2025 03:55 PM EasternExtended Trading$1.52 +0.01 (+1.00%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Inozyme Pharma NASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Lifecore Biomedical NASDAQ:LFCR$7.24 -0.52 (-6.70%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$7.28 +0.04 (+0.48%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
